Cancer Precision Medicine
Photo: Axel Henriksson
Precision medicine is a treatment approach customised to each individual patient. In the research programme Cancer Precision Medicine, we study a number of factors that could be used to develop such personalised treatments.
Because no two cancers are precisely alike, therapies often need to be tailored to specific tumours and patients to be effective. In cancer, precision medicine uses specific information about a person’s tumour to help make a diagnosis, plan treatment, monitor treatment response, or make a prognosis.
In our research programme, we aim to understand how factors such as genetics, epigenetics, molecular mechanisms, proteins, biomarkers, cellular processes, tumour biology and epidemiology can form a basis to find the best approach to prevent or treat the disease. Our research ranges all the way from bench to bedside.
Research groups
- Panagiotis Baliakas – Molecular genetics of hematological malignancies
- Jan Dumanski – Molecular oncology
- Ingrid Glimelius – Clinical, epidemiological and tumour biology studies of different cancer forms
- Helena Jernberg Wiklund – Targeting epigenetic regulators to develop novel therapeutic strategies and precision medicine in human haematological cancers
- Birgitta Johansson – Caring sciences in oncology care
- Cecilia Lindskog Bergström – A spatio-temporal single-cell type map of human tissues
- Magnus Lindskog – Clinical and epidemiological studies to identify optimal treatment strategies for chemo-resistant cancers
- Marika Nestor – Novel cancer-targeting strategies for improved molecular radiotherapy
- Peter Nygren – New and individualised cancer treatment
- Tobias Sjöblom – Finding and understanding cancer-causing molecular alterations
- Bo Stenerlöw – Radiation biology and DNA repair
- Vladimir Tolmachev – Scaffold protein-based radionuclide tumour targeting